Viridian Therapeutics Stock Market Value
| VRDN Stock | USD 21.87 0.04 0.18% |
| Symbol | Viridian |
Viridian Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 0.005 | Quarterly Revenue Growth 0.194 | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Viridian Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viridian Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viridian Therapeutics.
| 10/30/2024 |
| 11/29/2024 |
If you would invest 0.00 in Viridian Therapeutics on October 30, 2024 and sell it all today you would earn a total of 0.00 from holding Viridian Therapeutics or generate 0.0% return on investment in Viridian Therapeutics over 30 days. Viridian Therapeutics is related to or competes with Nuvalent, Arcellx, Vaxcyte, Crinetics Pharmaceuticals, Cytokinetics, Structure Therapeutics, and Pliant Therapeutics. Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases More
Viridian Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viridian Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viridian Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.82 | |||
| Information Ratio | 0.1082 | |||
| Maximum Drawdown | 44.89 | |||
| Value At Risk | (5.29) | |||
| Potential Upside | 6.84 |
Viridian Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viridian Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viridian Therapeutics' standard deviation. In reality, there are many statistical measures that can use Viridian Therapeutics historical prices to predict the future Viridian Therapeutics' volatility.| Risk Adjusted Performance | 0.1094 | |||
| Jensen Alpha | 0.4797 | |||
| Total Risk Alpha | (0.11) | |||
| Sortino Ratio | 0.1514 | |||
| Treynor Ratio | 0.3733 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Viridian Therapeutics Backtested Returns
Viridian Therapeutics appears to be not too volatile, given 3 months investment horizon. Viridian Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.15, which indicates the firm had a 0.15% return per unit of risk over the last 3 months. By inspecting Viridian Therapeutics' technical indicators, you can evaluate if the expected return of 0.79% is justified by implied risk. Please review Viridian Therapeutics' Coefficient Of Variation of 759.95, semi deviation of 3.44, and Risk Adjusted Performance of 0.1094 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Viridian Therapeutics holds a performance score of 11. The entity has a beta of 1.86, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Viridian Therapeutics will likely underperform. Please check Viridian Therapeutics' downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether Viridian Therapeutics' existing price patterns will revert.
Auto-correlation | 0.02 |
Virtually no predictability
Viridian Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Viridian Therapeutics time series from 30th of October 2024 to 14th of November 2024 and 14th of November 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viridian Therapeutics price movement. The serial correlation of 0.02 indicates that only 2.0% of current Viridian Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.02 | |
| Spearman Rank Test | 0.35 | |
| Residual Average | 0.0 | |
| Price Variance | 0.73 |
Viridian Therapeutics lagged returns against current returns
Autocorrelation, which is Viridian Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Viridian Therapeutics' stock expected returns. We can calculate the autocorrelation of Viridian Therapeutics returns to help us make a trade decision. For example, suppose you find that Viridian Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Viridian Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Viridian Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Viridian Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Viridian Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Viridian Therapeutics Lagged Returns
When evaluating Viridian Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Viridian Therapeutics stock have on its future price. Viridian Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Viridian Therapeutics autocorrelation shows the relationship between Viridian Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Viridian Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Viridian Stock
Moving against Viridian Stock
| 0.62 | INAB | In8bio Inc | PairCorr |
| 0.53 | ELAN | Elanco Animal Health Potential Growth | PairCorr |
| 0.43 | INMB | INmune Bio | PairCorr |
| 0.39 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.36 | TAK | Takeda Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Viridian Therapeutics Correlation, Viridian Therapeutics Volatility and Viridian Therapeutics Alpha and Beta module to complement your research on Viridian Therapeutics. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Viridian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.